Australian stem cell and regenerative medicine firm Cynata Therapeutics (ASX: CYP) saw its shares leap as much as 15.5% to A$1.85, after it revealed that it has received an indicative, non-binding and conditional proposal from Japan’s Sumitomo Dainippon Pharma (TYO: 4506) regarding a possible acquisition at a price of $2.00 cash per share – around $202 million in total - by way of a scheme of arrangement.
The release advises that the Cynata board has decided to grant non-exclusive due diligence access to Sumitomo Dainippon Pharma.
It also stated that Cynata has continued engagement with certain other parties in relation to making a proposal. Cynata’s discussions with such other parties have ceased.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze